{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:08:23Z","timestamp":1795172903924,"version":"4.10.3"},"reference-count":289,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41573-023-00672-y","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T05:06:00Z","timestamp":1681880760000},"page":"449-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":688,"title":["Therapeutic strategies for COVID-19: progress and lessons learned"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8852-034X","authenticated-orcid":false,"given":"Guangdi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-2977","authenticated-orcid":false,"given":"Rolf","family":"Hilgenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-9276","authenticated-orcid":false,"given":"Richard","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1016\/j.cell.2021.08.017","volume":"184","author":"EC Holmes","year":"2021","unstructured":"Holmes, E. C. et al. The origins of SARS-CoV-2: a critical review. Cell 184, 4848\u20134856 (2021).","journal-title":"Cell"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"672_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/d41573-022-00074-6","volume":"21","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov. 21, 324\u2013326 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"672_CR6","doi-asserted-by":"crossref","unstructured":"Li, G. & De Clercq, E. in Antiviral Discovery for Highly Pathogenic Emerging Viruses (eds Mu\u00f1oz-Fontela, C. & Delgado, R.) 1\u201327 (Royal Society of Chemistry, 2022).","DOI":"10.1039\/9781788016858-00001"},{"key":"672_CR7","doi-asserted-by":"crossref","unstructured":"Li, G., Jing, X., Zhang, P. & De Clercq, E. in Encyclopedia of Virology (Fourth Edition) (eds Bamford, D. & Zuckerman, M.) Ch. 1, 121\u2013130 (Academic Press, 2021).","DOI":"10.1016\/B978-0-12-814515-9.00126-0"},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","volume":"27","author":"RM Meganck","year":"2021","unstructured":"Meganck, R. M. & Baric, R. S. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat. Med. 27, 401\u2013410 (2021).","journal-title":"Nat. Med."},{"key":"672_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 17, 35\u201356 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41564-021-00958-0","volume":"6","author":"J Baggen","year":"2021","unstructured":"Baggen, J., Vanstreels, E., Jansen, S. & Daelemans, D. Cellular host factors for SARS-CoV-2 infection. Nat. Microbiol. 6, 1219\u20131232 (2021).","journal-title":"Nat. Microbiol."},{"key":"672_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41569-020-00469-1","volume":"18","author":"SX Gu","year":"2021","unstructured":"Gu, S. X. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 18, 194\u2013209 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"672_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. & Perez, L. Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov. 21, 676\u2013696 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","volume":"21","author":"L Boike","year":"2022","unstructured":"Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881\u2013898 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00014-22","volume":"35","author":"H Zhou","year":"2022","unstructured":"Zhou, H. et al. Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant. Clin. Microbiol. Rev. 35, e0001422 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"672_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00109-21","volume":"34","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. SARS-CoV-2 antiviral therapy. Clin. Microbiol. Rev. 34, e0010921 (2021).","journal-title":"Clin. Microbiol. Rev."},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMcp2117115","volume":"386","author":"PK Drain","year":"2022","unstructured":"Drain, P. K. Rapid diagnostic testing for SARS-CoV-2. N. Engl. J. Med. 386, 264\u2013272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"672_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(21)02346-1","volume":"399","author":"RW Peeling","year":"2022","unstructured":"Peeling, R. W., Heymann, D. L., Teo, Y. Y. & Garcia, P. J. Diagnostics for COVID-19: moving from pandemic response to control. Lancet 399, 757\u2013768 (2022).","journal-title":"Lancet"},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","volume":"20","author":"MM Lamers","year":"2022","unstructured":"Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270\u2013284 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019Kovski","year":"2021","unstructured":"V\u2019Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"A Gupta","year":"2020","unstructured":"Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017\u20131032 (2020).","journal-title":"Nat. Med."},{"key":"672_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"672_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","volume":"23","author":"MS Diamond","year":"2022","unstructured":"Diamond, M. S. & Kanneganti, T. D. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 23, 165\u2013176 (2022).","journal-title":"Nat. Immunol."},{"key":"672_CR25","first-page":"178","volume":"21","author":"JM Minkoff","year":"2023","unstructured":"Minkoff, J. M. & tenOever, B. Innate immune evasion strategies of SARS-CoV-2. Nat. Rev. Microbiol. 21, 178\u2013194 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang, H. & Rao, Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 19, 685\u2013700 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23, 21\u201339 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"672_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","volume":"605","author":"MM DeGrace","year":"2022","unstructured":"DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature 605, 640\u2013652 (2022).","journal-title":"Nature"},{"key":"672_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","volume":"600","author":"J Li","year":"2021","unstructured":"Li, J., Lai, S., Gao, G. F. & Shi, W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature 600, 408\u2013418 (2021).","journal-title":"Nature"},{"key":"672_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S. & Yuen, K. Y. Coronaviruses \u2014 drug discovery and therapeutic options. Nat. Rev. Drug. Discov. 15, 327\u2013347 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu, L., Su, S., Yang, H. & Jiang, S. Antivirals with common targets against highly pathogenic viruses. Cell 184, 1604\u20131620 (2021).","journal-title":"Cell"},{"key":"672_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.chom.2020.08.004","volume":"28","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe 28, 586\u2013601.e586 (2020).","journal-title":"Cell Host Microbe"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"672_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.chom.2020.11.004","volume":"28","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe 28, 867\u2013879.e865 (2020).","journal-title":"Cell Host Microbe"},{"key":"672_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491\u2013495 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac724","author":"A Bhimraj","year":"2022","unstructured":"Bhimraj, A. et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac724 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 21, 112\u2013124 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR38","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).","journal-title":"Front. Immunol."},{"key":"672_CR39","doi-asserted-by":"publisher","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"YM Loo","year":"2022","unstructured":"Loo, Y. M. et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci. Transl. Med. 14, eabl8124 (2022).","journal-title":"Sci. Transl. Med."},{"key":"672_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00200-21","volume":"35","author":"D Focosi","year":"2022","unstructured":"Focosi, D. et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin. Microbiol. Rev. 35, e0020021 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"672_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.molmed.2022.02.005","volume":"28","author":"JW Senefeld","year":"2022","unstructured":"Senefeld, J. W., Casadevall, A. & Joyner, M. J. Convalescent plasma to deliver therapeutic antibodies against COVID-19. Trends Mol. Med. 28, 435\u2013436 (2022).","journal-title":"Trends Mol. Med."},{"key":"672_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47331","volume":"5","author":"AB Troxel","year":"2022","unstructured":"Troxel, A. B. et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw. Open. 5, e2147331 (2022).","journal-title":"JAMA Netw. Open."},{"key":"672_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29911-3","volume":"13","author":"P Millat-Martinez","year":"2022","unstructured":"Millat-Martinez, P. et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat. Commun. 13, 2583 (2022).","journal-title":"Nat. Commun."},{"key":"672_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185\u20131191 (2020).","journal-title":"Nat. Microbiol."},{"key":"672_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"672_CR46","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e1021 (2020).","journal-title":"Cell"},{"key":"672_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382\u2013393 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR48","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"672_CR49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"672_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","volume":"399","author":"Recovery Collaborative Group.","year":"2022","unstructured":"Recovery Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665\u2013676 (2022).","journal-title":"Lancet"},{"key":"672_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/M21-3507","volume":"175","author":"Activ-Tico Bamlanivimab Study Group.","year":"2021","unstructured":"Activ-Tico Bamlanivimab Study Group. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann. Intern. Med. 175, 234\u2013243 (2021).","journal-title":"Ann. Intern. Med."},{"key":"672_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"672_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker, L. M. & Burton, D. R. Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray. Nat. Rev. Immunol. 18, 297\u2013308 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","volume":"32","author":"YQ Deng","year":"2022","unstructured":"Deng, Y. Q. et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 32, 375\u2013382 (2022).","journal-title":"Cell Res."},{"key":"672_CR55","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol. Immunol. 17, 765\u2013767 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"672_CR56","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","volume":"363","author":"S Liu","year":"2004","unstructured":"Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938\u2013947 (2004).","journal-title":"Lancet"},{"key":"672_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4067","volume":"5","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014).","journal-title":"Nat. Commun."},{"key":"672_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/365113a0","volume":"365","author":"S Jiang","year":"1993","unstructured":"Jiang, S., Lin, K., Strick, N. & Neurath, A. R. HIV-1 inhibition by a peptide. Nature 365, 113 (1993).","journal-title":"Nature"},{"key":"672_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28143","volume":"95","author":"Q Lan","year":"2023","unstructured":"Lan, Q. et al. Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases. J. Med. Virol. 95, e28143 (2023).","journal-title":"J. Med. Virol."},{"key":"672_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"M Muttenthaler","year":"2021","unstructured":"Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309\u2013325 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR61","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","volume":"19","author":"AP Davenport","year":"2020","unstructured":"Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H. & Maguire, J. J. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug Discov. 19, 389\u2013413 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR62","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7326\/M22-1503","volume":"175","author":"ACTIV-3\/TICO Study Group.","year":"2022","unstructured":"ACTIV-3\/TICO Study Group. Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann. Intern. Med. 175, 1266\u20131274 (2022).","journal-title":"Ann. Intern. Med."},{"key":"672_CR63","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"672_CR64","doi-asserted-by":"publisher","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut, W. et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci. Adv. 6, eabd4596 (2020).","journal-title":"Sci. Adv."},{"key":"672_CR65","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR66","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s13238-022-00909-3","volume":"13","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell 13, 940\u2013953 (2022).","journal-title":"Protein Cell"},{"key":"672_CR67","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1039\/D0SC02646H","volume":"11","author":"K Sargsyan","year":"2020","unstructured":"Sargsyan, K. et al. Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors. Chem. Sci. 11, 9904\u20139909 (2020).","journal-title":"Chem. Sci."},{"key":"672_CR68","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"H Tan","year":"2022","unstructured":"Tan, H., Hu, Y., Jadhav, P., Tan, B. & Wang, J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 65, 7561\u20137580 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR69","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1073\/pnas.0510851103","volume":"103","author":"K Ratia","year":"2006","unstructured":"Ratia, K. et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl Acad. Sci. USA 103, 5717\u20135722 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan, J. A., Jacq, X., Martin, N. M. & Jackson, S. P. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 17, 57\u201378 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR71","doi-asserted-by":"publisher","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","volume":"64","author":"K Gao","year":"2021","unstructured":"Gao, K. et al. Perspectives on SARS-CoV-2 main protease inhibitors. J. Med. Chem. 64, 16922\u201316955 (2021).","journal-title":"J. Med. Chem."},{"key":"672_CR72","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/cells8030264","volume":"8","author":"E Vidak","year":"2019","unstructured":"Vidak, E., Javorsek, U., Vizovisek, M. & Turk, B. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells 8, 264 (2019).","journal-title":"Cells"},{"key":"672_CR73","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"672_CR74","doi-asserted-by":"publisher","first-page":"13328","DOI":"10.1021\/acs.jmedchem.2c01131","volume":"65","author":"MS Cooper","year":"2022","unstructured":"Cooper, M. S. et al. Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease. J. Med. Chem. 65, 13328\u201313342 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"672_CR76","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"AK Ghosh","year":"2016","unstructured":"Ghosh, A. K., Osswald, H. L. & Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J. Med. Chem. 59, 5172\u20135208 (2016).","journal-title":"J. Med. Chem."},{"key":"672_CR77","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 13, 689\u2013693 (2022).","journal-title":"Protein Cell"},{"key":"672_CR78","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"672_CR79","doi-asserted-by":"publisher","first-page":"101972","DOI":"10.1016\/j.jbc.2022.101972","volume":"298","author":"SE Greasley","year":"2022","unstructured":"Greasley, S. E. et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J. Biol. Chem. 298, 101972 (2022).","journal-title":"J. Biol. Chem."},{"key":"672_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","volume":"607","author":"R Uraki","year":"2022","unstructured":"Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119\u2013127 (2022).","journal-title":"Nature"},{"key":"672_CR81","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1021\/acs.jmedchem.1c02214","volume":"65","author":"TR Malla","year":"2022","unstructured":"Malla, T. R. et al. Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine. J. Med. Chem. 65, 7682\u20137696 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23313-7","volume":"12","author":"K Amporndanai","year":"2021","unstructured":"Amporndanai, K. et al. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat. Commun. 12, 3061 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR83","doi-asserted-by":"publisher","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","volume":"64","author":"AK Ghosh","year":"2021","unstructured":"Ghosh, A. K. et al. Indole chloropyridinyl ester-derived SARS-CoV-2 3 CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure-activity relationship, and X-ray structural studies. J. Med. Chem. 64, 14702\u201314714 (2021).","journal-title":"J. Med. Chem."},{"key":"672_CR84","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1021\/acs.jmedchem.2c00224","volume":"65","author":"CS Dampalla","year":"2022","unstructured":"Dampalla, C. S. et al. Structure-guided design of potent spirocyclic inhibitors of severe acute respiratory syndrome coronavirus-2 3C-like protease. J. Med. Chem. 65, 7818\u20137832 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23751-3","volume":"12","author":"H Su","year":"2021","unstructured":"Su, H. et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat. Commun. 12, 3623 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR86","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac933","author":"H Mukae","year":"2022","unstructured":"Mukae, H. et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac933 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR88","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","volume":"63","author":"RL Hoffman","year":"2020","unstructured":"Hoffman, R. L. et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 63, 12725\u201312747 (2020).","journal-title":"J. Med. Chem."},{"key":"672_CR89","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","volume":"17","author":"W Rut","year":"2021","unstructured":"Rut, W. et al. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 17, 222\u2013228 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"672_CR90","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"672_CR91","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1056\/NEJMc2205944","volume":"387","author":"AS Anderson","year":"2022","unstructured":"Anderson, A. S., Caubel, P. & Rusnak, J. M., EPIC-HR Investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19. N. Engl. J. Med. 387, 1047\u20131049 (2022).","journal-title":"N. Engl. J. Med."},{"key":"672_CR92","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"672_CR93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-biochem-052521-115653","volume":"91","author":"Z Lou","year":"2022","unstructured":"Lou, Z. & Rao, Z. The life of SARS-CoV-2 inside cells: replication-transcription complex assembly and function. Annu. Rev. Biochem. 91, 381\u2013401 (2022).","journal-title":"Annu. Rev. Biochem."},{"key":"672_CR94","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2020.11.016","volume":"184","author":"L Yan","year":"2021","unstructured":"Yan, L. et al. Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis. Cell 184, 184\u2013193.e110 (2021).","journal-title":"Cell"},{"key":"672_CR95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022310118","volume":"118","author":"H Slanina","year":"2021","unstructured":"Slanina, H. et al. Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proc. Natl Acad. Sci. USA 118, e2022310118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR96","doi-asserted-by":"publisher","first-page":"13019","DOI":"10.1093\/nar\/gkab1160","volume":"49","author":"AP Walker","year":"2021","unstructured":"Walker, A. P. et al. The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme. Nucleic Acids Res. 49, 13019\u201313030 (2021).","journal-title":"Nucleic Acids Res."},{"key":"672_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28113-1","volume":"13","author":"A Shannon","year":"2022","unstructured":"Shannon, A. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 13, 621 (2022).","journal-title":"Nat. Commun."},{"key":"672_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009384","volume":"17","author":"A Dwivedy","year":"2021","unstructured":"Dwivedy, A. et al. Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2. PLoS Comput. Biol. 17, e1009384 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"672_CR99","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","volume":"14","author":"G Li","year":"2022","unstructured":"Li, G., Wang, Y. & De Clercq, E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm. Sin. B 14, 1567\u20131590 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"672_CR100","doi-asserted-by":"publisher","first-page":"135965352210827","DOI":"10.1177\/13596535221082773","volume":"27","author":"T Cihlar","year":"2022","unstructured":"Cihlar, T. & Mackman, R. L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 27, 13596535221082773 (2022).","journal-title":"Antivir. Ther."},{"key":"672_CR101","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","volume":"22","author":"A Cho","year":"2012","unstructured":"Cho, A. et al. Synthesis and antiviral activity of a series of 1\u2019-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 22, 2705\u20132707 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"672_CR102","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel, D. et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J. Med. Chem. 60, 1648\u20131661 (2017).","journal-title":"J. Med. Chem."},{"key":"672_CR103","doi-asserted-by":"publisher","first-page":"e01814","DOI":"10.1128\/AAC.01814-20","volume":"65","author":"MM Aleissa","year":"2020","unstructured":"Aleissa, M. M. et al. New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob. Agents Chemother. 65, e01814\u2013e01820 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"672_CR104","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"672_CR105","doi-asserted-by":"publisher","first-page":"e00162-20","DOI":"10.1128\/CMR.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin, J. J., Suarez, I., Priesner, V., Fatkenheuer, G. & Rybniker, J. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 34, e00162-20 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"672_CR106","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785\u20136797 (2020).","journal-title":"J. Biol. Chem."},{"key":"672_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"G Kokic","year":"2021","unstructured":"Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR108","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"399","author":"WHO Solidarity Trial Consortium.","year":"2022","unstructured":"WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941\u20131953 (2022).","journal-title":"Lancet"},{"key":"672_CR109","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","volume":"22","author":"F Ader","year":"2022","unstructured":"Ader, F. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 22, 209\u2013221 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"672_CR110","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7326\/M20-8101","volume":"174","author":"A Qaseem","year":"2021","unstructured":"Qaseem, A. et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (Version 2). Ann. Intern. Med. 174, 673\u2013679 (2021).","journal-title":"Ann. Intern. Med."},{"key":"672_CR111","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.apsb.2021.03.028","volume":"11","author":"J Xie","year":"2021","unstructured":"Xie, J. & Wang, Z. Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. Acta Pharm. Sin. B 11, 1607\u20131616 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"672_CR112","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of Covid-19. N. Engl. J. Med. 388, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"672_CR113","doi-asserted-by":"publisher","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"M Toots","year":"2019","unstructured":"Toots, M. et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11, eaax5866 (2019).","journal-title":"Sci. Transl. Med."},{"key":"672_CR114","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0027-5107(80)90218-3","volume":"72","author":"C Janion","year":"1980","unstructured":"Janion, C. & Glickman, B. W. N4-hydroxycytidine: a mutagen specific for AT to GC transitions. Mutat. Res. 72, 43\u201347 (1980).","journal-title":"Mutat. Res."},{"key":"672_CR115","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"672_CR116","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"672_CR117","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med."},{"key":"672_CR118","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 401, 281\u2013293 (2023).","journal-title":"Lancet"},{"key":"672_CR119","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/ciac687","volume":"76","author":"TCF Yip","year":"2023","unstructured":"Yip, T. C. F. et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. Clin. Infect. Dis. 76, e26\u2013e33 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR120","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"672_CR121","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1126\/science.abn0048","volume":"375","author":"R Swanstrom","year":"2022","unstructured":"Swanstrom, R. & Schinazi, R. F. Lethal mutagenesis as an antiviral strategy. Science 375, 497\u2013498 (2022).","journal-title":"Science"},{"key":"672_CR122","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","volume":"297","author":"CJ Gordon","year":"2021","unstructured":"Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F. & Gotte, M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 297, 100770 (2021).","journal-title":"J. Biol. Chem."},{"key":"672_CR123","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jiab247","volume":"224","author":"S Zhou","year":"2021","unstructured":"Zhou, S. et al. \u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 224, 415\u2013419 (2021).","journal-title":"J. Infect. Dis."},{"key":"672_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18463-z","volume":"11","author":"A Shannon","year":"2020","unstructured":"Shannon, A. et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 11, 4682 (2020).","journal-title":"Nat. Commun."},{"key":"672_CR125","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.4155\/fmc-2018-0457","volume":"11","author":"C Perales","year":"2019","unstructured":"Perales, C. et al. The increasing impact of lethal mutagenesis of viruses. Future Med. Chem. 11, 1645\u20131657 (2019).","journal-title":"Future Med. Chem."},{"key":"672_CR126","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Y Furuta","year":"2009","unstructured":"Furuta, Y. et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antivir. Res. 82, 95\u2013102 (2009).","journal-title":"Antivir. Res."},{"key":"672_CR127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021946118","volume":"118","author":"K Naydenova","year":"2021","unstructured":"Naydenova, K. et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc. Natl Acad. Sci. USA 118, e2021946118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR128","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA 117, 26955\u201326965 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR129","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","volume":"28","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed, M. et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin. Microbiol. Infect. 28, 602\u2013608 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"672_CR130","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciac712","volume":"76","author":"Y Golan","year":"2023","unstructured":"Golan, Y. et al. Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial. Clin. Infect. Dis. 76, e10\u2013e17 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR131","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/cid\/ciac312","volume":"75","author":"M Holubar","year":"2022","unstructured":"Holubar, M. et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. Clin. Infect. Dis. 75, 1883\u20131892 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389","volume":"11","author":"TH Nguyen","year":"2017","unstructured":"Nguyen, T. H. et al. Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 11, e0005389 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"672_CR133","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153165","volume":"7","author":"RP Bennett","year":"2022","unstructured":"Bennett, R. P. et al. Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties. JCI Insight 7, e153165 (2022).","journal-title":"JCI Insight"},{"key":"672_CR134","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","volume":"28","author":"W Yin","year":"2021","unstructured":"Yin, W. et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat. Struct. Mol. Biol. 28, 319\u2013325 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"672_CR135","doi-asserted-by":"publisher","first-page":"e01168-19","DOI":"10.1128\/AAC.01168-19","volume":"64","author":"N Wiedemar","year":"2020","unstructured":"Wiedemar, N., Hauser, D. A. & Maser, P. 100 years of suramin. Antimicrob. Agents Chemother. 64, e01168-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"672_CR136","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","volume":"182","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell 182, 1560\u20131573.e1513 (2020).","journal-title":"Cell"},{"key":"672_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25166-6","volume":"12","author":"JA Newman","year":"2021","unstructured":"Newman, J. A. et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun. 12, 4848 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR138","doi-asserted-by":"publisher","first-page":"602162","DOI":"10.3389\/fchem.2020.602162","volume":"8","author":"F Squeglia","year":"2020","unstructured":"Squeglia, F., Romano, M., Ruggiero, A., Maga, G. & Berisio, R. Host DDX helicases as possible SARS-CoV-2 proviral factors: a structural overview of their hijacking through multiple viral proteins. Front. Chem. 8, 602162 (2020).","journal-title":"Front. Chem."},{"key":"672_CR139","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/13543776.2022.2113873","volume":"32","author":"C Gege","year":"2022","unstructured":"Gege, C. & Kleymann, G. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018\/127207 and WO2020\/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037. Expert Opin. Ther. Pat. 32, 933\u2013937 (2022).","journal-title":"Expert Opin. Ther. Pat."},{"key":"672_CR140","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1126\/science.abi9310","volume":"373","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme. Science 373, 1142\u20131146 (2021).","journal-title":"Science"},{"key":"672_CR141","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1016\/j.cell.2021.05.033","volume":"184","author":"L Yan","year":"2021","unstructured":"Yan, L. et al. Coupling of N7-methyltransferase and 3\u2032\u20135\u2032 exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell 184, 3474\u20133485.e3411 (2021).","journal-title":"Cell"},{"key":"672_CR142","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/nar\/gkab1303","volume":"50","author":"HT Baddock","year":"2022","unstructured":"Baddock, H. T. et al. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. Nucleic Acids Res. 50, 1484\u20131500 (2022).","journal-title":"Nucleic Acids Res."},{"key":"672_CR143","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1073\/pnas.1718806115","volume":"115","author":"F Ferron","year":"2018","unstructured":"Ferron, F. et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl Acad. Sci. USA 115, E162\u2013E171 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR144","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/nar\/gkab1279","volume":"50","author":"R Nencka","year":"2022","unstructured":"Nencka, R. et al. Coronaviral RNA-methyltransferases: function, structure and inhibition. Nucleic Acids Res. 50, 635\u2013650 (2022).","journal-title":"Nucleic Acids Res."},{"key":"672_CR145","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1021\/acs.jmedchem.2c00120","volume":"65","author":"R Ahmed-Belkacem","year":"2022","unstructured":"Ahmed-Belkacem, R. et al. Potent Inhibition of SARS-CoV-2 NSP14 N7-methyltransferase by sulfonamide-based bisubstrate analogues. J. Med. Chem. 65, 6231\u20136249 (2022).","journal-title":"J. Med. Chem."},{"key":"672_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20608-z","volume":"12","author":"MC Pillon","year":"2021","unstructured":"Pillon, M. C. et al. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat. Commun. 12, 636 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR147","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/pro.3873","volume":"29","author":"Y Kim","year":"2020","unstructured":"Kim, Y. et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci. 29, 1596\u20131605 (2020).","journal-title":"Protein Sci."},{"key":"672_CR148","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s42003-021-01735-9","volume":"4","author":"Y Kim","year":"2021","unstructured":"Kim, Y. et al. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun. Biol. 4, 193 (2021).","journal-title":"Commun. Biol."},{"key":"672_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23594-y","volume":"12","author":"T Viswanathan","year":"2021","unstructured":"Viswanathan, T. et al. A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2\u2019-O methylation of its first nucleotide. Nat. Commun. 12, 3287 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR150","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acsmedchemlett.1c00140","volume":"12","author":"O Bobileva","year":"2021","unstructured":"Bobileva, O. et al. Potent SARS-CoV-2 mRNA Cap methyltransferase inhibitors by bioisosteric replacement of methionine in SAM cosubstrate. ACS Med. Chem. Lett. 12, 1102\u20131107 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"672_CR151","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111608","volume":"41","author":"V Bergant","year":"2022","unstructured":"Bergant, V. et al. Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2\u2032-O-ribose methyltransferases. EMBO J. 41, e111608 (2022).","journal-title":"EMBO J."},{"key":"672_CR152","doi-asserted-by":"publisher","first-page":"20698","DOI":"10.18632\/oncotarget.25062","volume":"9","author":"E Lhuissier","year":"2018","unstructured":"Lhuissier, E. et al. Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice. Oncotarget 9, 20698\u201320708 (2018).","journal-title":"Oncotarget"},{"key":"672_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21953-3","volume":"12","author":"J Cubuk","year":"2021","unstructured":"Cubuk, J. et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun. 12, 1936 (2021).","journal-title":"Nat. Commun."},{"key":"672_CR154","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41556-021-00710-0","volume":"23","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat. Cell Biol. 23, 718\u2013732 (2021).","journal-title":"Nat. Cell Biol."},{"key":"672_CR155","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","volume":"7","author":"W Yan","year":"2022","unstructured":"Yan, W., Zheng, Y., Zeng, X., He, B. & Cheng, W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target. Ther. 7, 26 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"672_CR156","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.antiviral.2014.06.013","volume":"109","author":"DX Liu","year":"2014","unstructured":"Liu, D. X., Fung, T. S., Chong, K. K., Shukla, A. & Hilgenfeld, R. Accessory proteins of SARS-CoV and other coronaviruses. Antivir. Res. 109, 97\u2013109 (2014).","journal-title":"Antivir. Res."},{"key":"672_CR157","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117198119","volume":"119","author":"SM Vora","year":"2022","unstructured":"Vora, S. M. et al. Targeting stem-loop 1 of the SARS-CoV-2 5\u2019 UTR to suppress viral translation and Nsp1 evasion. Proc. Natl Acad. Sci. USA 119, e2117198119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR158","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/nar\/gkab1248","volume":"50","author":"S Ambike","year":"2022","unstructured":"Ambike, S. et al. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res. 50, 333\u2013349 (2022).","journal-title":"Nucleic Acids Res."},{"key":"672_CR159","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115298","volume":"14","author":"YC Chang","year":"2022","unstructured":"Chang, Y. C. et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol. Med. 14, e15298 (2022).","journal-title":"EMBO Mol. Med."},{"key":"672_CR160","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"672_CR161","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1097\/QAD.0000000000003218","volume":"36","author":"Q Le Hingrat","year":"2022","unstructured":"Le Hingrat, Q. et al. Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates. AIDS 36, 1055\u20131060 (2022).","journal-title":"AIDS"},{"key":"672_CR162","doi-asserted-by":"publisher","first-page":"fuaa057","DOI":"10.1093\/femsre\/fuaa057","volume":"45","author":"JK Millet","year":"2021","unstructured":"Millet, J. K., Jaimes, J. A. & Whittaker, G. R. Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiol. Rev. 45, fuaa057 (2021).","journal-title":"FEMS Microbiol. Rev."},{"key":"672_CR163","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"672_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apsb.2020.10.006","volume":"11","author":"J Bian","year":"2021","unstructured":"Bian, J. & Li, Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm. Sin. B 11, 1\u201312 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"672_CR165","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s42003-021-01736-8","volume":"4","author":"P Karoyan","year":"2021","unstructured":"Karoyan, P. et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 4, 197 (2021).","journal-title":"Commun. Biol."},{"key":"672_CR166","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115230","volume":"14","author":"V Monteil","year":"2022","unstructured":"Monteil, V. et al. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol. Med. 14, e15230 (2022).","journal-title":"EMBO Mol. Med."},{"key":"672_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202115695","volume":"61","author":"YH Shin","year":"2022","unstructured":"Shin, Y. H. et al. Inhibition of ACE2-spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry. Angew. Chem. Int. Ed. 61, e202115695 (2022).","journal-title":"Angew. Chem. Int. Ed."},{"key":"672_CR168","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"672_CR169","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107821","volume":"40","author":"J Koch","year":"2021","unstructured":"Koch, J. et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 40, e107821 (2021).","journal-title":"EMBO J."},{"key":"672_CR170","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154305","volume":"23","author":"G Jocher","year":"2022","unstructured":"Jocher, G. et al. ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Rep. 23, e54305 (2022).","journal-title":"EMBO Rep."},{"key":"672_CR171","doi-asserted-by":"publisher","first-page":"108254","DOI":"10.1016\/j.celrep.2020.108254","volume":"33","author":"YW Cheng","year":"2020","unstructured":"Cheng, Y. W. et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 33, 108254 (2020).","journal-title":"Cell Rep."},{"key":"672_CR172","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"672_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009500","volume":"17","author":"M Laporte","year":"2021","unstructured":"Laporte, M. et al. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathog. 17, e1009500 (2021).","journal-title":"PLoS Pathog."},{"key":"672_CR174","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","volume":"6","author":"TP Peacock","year":"2021","unstructured":"Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899\u2013909 (2021).","journal-title":"Nat. Microbiol."},{"key":"672_CR175","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","volume":"603","author":"KPY Hui","year":"2022","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715\u2013720 (2022).","journal-title":"Nature"},{"key":"672_CR176","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 603, 706\u2013714 (2022).","journal-title":"Nature"},{"key":"672_CR177","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00970-21","volume":"12","author":"K Li","year":"2021","unstructured":"Li, K., Meyerholz, D. K., Bartlett, J. A. & McCray, P. B. Jr The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. mBio 12, e0097021 (2021).","journal-title":"mBio"},{"key":"672_CR178","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini, T. et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615, 134\u2013142 (2023).","journal-title":"Nature"},{"key":"672_CR179","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41556-021-00821-8","volume":"24","author":"AJ Samelson","year":"2022","unstructured":"Samelson, A. J. et al. BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nat. Cell Biol. 24, 24\u201334 (2022).","journal-title":"Nat. Cell Biol."},{"key":"672_CR180","first-page":"785","volume":"609","author":"H Chu","year":"2022","unstructured":"Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785\u2013792 (2022).","journal-title":"Nature"},{"key":"672_CR181","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-021-00760-8","volume":"6","author":"J Geng","year":"2021","unstructured":"Geng, J. et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal. Transduct. Target. Ther. 6, 347 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"672_CR182","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"KM White","year":"2021","unstructured":"White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371, 926\u2013931 (2021).","journal-title":"Science"},{"key":"672_CR183","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113401118","volume":"118","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc. Natl Acad. Sci. USA 118, e2113401118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR184","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","volume":"594","author":"L Braga","year":"2021","unstructured":"Braga, L. et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 594, 88\u201393 (2021).","journal-title":"Nature"},{"key":"672_CR185","doi-asserted-by":"publisher","first-page":"EVIDoa2200145","DOI":"10.1056\/EVIDoa2200145","volume":"1","author":"KG Barnette","year":"2022","unstructured":"Barnette, K. G. et al. Oral Sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis. NEJM Evid. 1, EVIDoa2200145 (2022).","journal-title":"NEJM Evid."},{"key":"672_CR186","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41392-023-01323-9","volume":"8","author":"H Bian","year":"2023","unstructured":"Bian, H. et al. Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2\/3, randomized, third-party double-blind clinical trial. Signal. Transduct. Target. Ther. 8, 46 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"672_CR187","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR188","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.abm8108","volume":"375","author":"M Merad","year":"2022","unstructured":"Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and immunopathology of COVID-19. Science 375, 1122\u20131127 (2022).","journal-title":"Science"},{"key":"672_CR189","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","volume":"370","author":"A Agarwal","year":"2020","unstructured":"Agarwal, A. et al. A living WHO guideline on drugs for covid-19. BMJ 370, m3379 (2020).","journal-title":"BMJ"},{"key":"672_CR190","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39\u201350 (2022).","journal-title":"Nat. Med."},{"key":"672_CR191","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233\u2013247 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR192","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","volume":"16","author":"RS Hardy","year":"2020","unstructured":"Hardy, R. S., Raza, K. & Cooper, M. S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat. Rev. Rheumatol. 16, 133\u2013144 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"672_CR193","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41591-021-01576-3","volume":"28","author":"S Sinha","year":"2022","unstructured":"Sinha, S. et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat. Med. 28, 201\u2013211 (2022).","journal-title":"Nat. Med."},{"key":"672_CR194","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/healthcare10040645","volume":"10","author":"J Kim","year":"2022","unstructured":"Kim, J., Miyazaki, K., Shah, P., Kozai, L. & Kewcharoen, J. Association between mineralocorticoid receptor antagonist and mortality in SARS-CoV-2 patients: a systematic review and meta-analysis. Healthcare 10, 645 (2022).","journal-title":"Healthcare"},{"key":"672_CR195","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"The RECOVERY Collaborative Group.","year":"2021","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR196","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/annrheumdis-2021-221366","volume":"81","author":"A Alunno","year":"2022","unstructured":"Alunno, A. et al. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann. Rheum. Dis. 81, 34\u201340 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"672_CR197","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","volume":"10","author":"CR Wolfe","year":"2022","unstructured":"Wolfe, C. R. et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir. Med. 10, 888\u2013899 (2022).","journal-title":"Lancet Respir. Med."},{"key":"672_CR198","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","volume":"398","author":"LM Yu","year":"2021","unstructured":"Yu, L. M. et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 398, 843\u2013855 (2021).","journal-title":"Lancet"},{"key":"672_CR199","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","volume":"9","author":"S Ramakrishnan","year":"2021","unstructured":"Ramakrishnan, S. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 9, 763\u2013772 (2021).","journal-title":"Lancet Respir. Med."},{"key":"672_CR200","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","volume":"182","author":"BM Clemency","year":"2022","unstructured":"Clemency, B. M. et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern. Med. 182, 42\u201349 (2022).","journal-title":"JAMA Intern. Med."},{"key":"672_CR201","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068060","volume":"375","author":"N Ezer","year":"2021","unstructured":"Ezer, N. et al. Inhaled and intranasal ciclesonide for the treatment of Covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ 375, e068060 (2021).","journal-title":"BMJ"},{"key":"672_CR202","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu, D. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 9, 30 (2013).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"672_CR203","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S2213-2600(20)30503-8","volume":"8","author":"MA Matthay","year":"2020","unstructured":"Matthay, M. A. & Thompson, B. T. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. Lancet Respir. Med. 8, 1170\u20131172 (2020).","journal-title":"Lancet Respir. Med."},{"key":"672_CR204","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK\u2013STAT pathway at 30: much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"672_CR205","doi-asserted-by":"publisher","first-page":"eabe4724","DOI":"10.1126\/sciadv.abe4724","volume":"7","author":"J Stebbing","year":"2021","unstructured":"Stebbing, J. et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv. 7, eabe4724 (2021).","journal-title":"Sci. Adv."},{"key":"672_CR206","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte, V. et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest. 130, 6409\u20136416 (2020).","journal-title":"J. Clin. Invest."},{"key":"672_CR207","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"RECOVERY Collaborative Group.","year":"2022","unstructured":"RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 359\u2013368 (2022).","journal-title":"Lancet"},{"key":"672_CR208","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407\u20131418 (2021).","journal-title":"Lancet Respir. Med."},{"key":"672_CR209","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795\u2013807 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR210","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimaraes","year":"2021","unstructured":"Guimaraes, P. O. et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 385, 406\u2013415 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR211","doi-asserted-by":"publisher","first-page":"eabg0833","DOI":"10.1126\/sciimmunol.abg0833","volume":"6","author":"B Yan","year":"2021","unstructured":"Yan, B. et al. SARS-CoV-2 drives JAK1\/2-dependent local complement hyperactivation. Sci. Immunol. 6, eabg0833 (2021).","journal-title":"Sci. Immunol."},{"key":"672_CR212","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233\u20131244 (2020).","journal-title":"Lancet Respir. Med."},{"key":"672_CR213","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"672_CR214","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 384, 1503\u20131516 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR215","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"REMAP-CAP Investigators.","year":"2021","unstructured":"REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR216","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2022.23257","volume":"329","author":"Writing Committee for the REMAP-CAP Investigators.","year":"2022","unstructured":"Writing Committee for the REMAP-CAP Investigators. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA 329, 39\u201351 (2022).","journal-title":"JAMA"},{"key":"672_CR217","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1097\/CCM.0000000000005591","volume":"50","author":"BE Lonze","year":"2022","unstructured":"Lonze, B. E. et al. A randomized double-blinded placebo controlled trial of clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Crit. Care Med. 50, 1348\u20131359 (2022).","journal-title":"Crit. Care Med."},{"key":"672_CR218","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","volume":"10","author":"Z Temesgen","year":"2022","unstructured":"Temesgen, Z. et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir. Med. 10, 237\u2013246 (2022).","journal-title":"Lancet Respir. Med."},{"key":"672_CR219","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1164\/rccm.202108-1859OC","volume":"205","author":"GJ Criner","year":"2022","unstructured":"Criner, G. J. et al. Anti-granulocyte-macrophage colony-stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 205, 1290\u20131299 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"672_CR220","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","volume":"10","author":"BA Fisher","year":"2022","unstructured":"Fisher, B. A. et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir. Med. 10, 255\u2013266 (2022).","journal-title":"Lancet Respir. Med."},{"key":"672_CR221","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.2021.9508","volume":"326","author":"R Caricchio","year":"2021","unstructured":"Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA 326, 230\u2013239 (2021).","journal-title":"JAMA"},{"key":"672_CR222","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/23744235.2022.2066171","volume":"54","author":"GG Resende","year":"2022","unstructured":"Resende, G. G. et al. Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients - the BISHOP study. Infect. Dis. 54, 591\u2013599 (2022).","journal-title":"Infect. Dis."},{"key":"672_CR223","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"672_CR224","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O\u2019Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87\u2013103 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR225","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.immuni.2021.01.017","volume":"54","author":"DA Hoagland","year":"2021","unstructured":"Hoagland, D. A. et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity 54, 557\u2013570.e555 (2021).","journal-title":"Immunity"},{"key":"672_CR226","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1093\/cid\/ciac523","volume":"76","author":"AR Tam","year":"2023","unstructured":"Tam, A. R. et al. Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. Clin. Infect. Dis. 76, e216\u2013e226 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR227","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa2209760","volume":"388","author":"G Reis","year":"2023","unstructured":"Reis, G. et al. Early treatment with pegylated interferon lambda for Covid-19. N. Engl. J. Med. 388, 518\u2013528 (2023).","journal-title":"N. Engl. J. Med."},{"key":"672_CR228","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHO Solidarity Trial Consortium.","year":"2021","unstructured":"WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N. Engl. J. Med. 384, 497\u2013511 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR229","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 1365\u20131376 (2021).","journal-title":"Lancet Respir. Med."},{"key":"672_CR230","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S1473-3099(22)00433-9","volume":"23","author":"N Perico","year":"2023","unstructured":"Perico, N., Cortinovis, M., Suter, F. & Remuzzi, G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect. Dis. 23, e22\u2013e33 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"672_CR231","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.cell.2021.03.051","volume":"184","author":"JSY Ho","year":"2021","unstructured":"Ho, J. S. Y. et al. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell 184, 2618\u20132632.e2617 (2021).","journal-title":"Cell"},{"key":"672_CR232","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","volume":"588","author":"J Carvelli","year":"2020","unstructured":"Carvelli, J. et al. Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature 588, 146\u2013150 (2020).","journal-title":"Nature"},{"key":"672_CR233","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar, A. P. J. et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10, 1137\u20131146 (2022).","journal-title":"Lancet Respir. Med."},{"key":"672_CR234","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","volume":"29","author":"MB Malas","year":"2020","unstructured":"Malas, M. B. et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. eClinicalMedicine 29, 100639 (2020).","journal-title":"eClinicalMedicine"},{"key":"672_CR235","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jacc.2021.12.023","volume":"79","author":"ME Farkouh","year":"2022","unstructured":"Farkouh, M. E. et al. Anticoagulation in patients with COVID-19: JACC review topic of the week. J. Am. Coll. Cardiol. 79, 917\u2013928 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"672_CR236","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","volume":"385","author":"ATTACC Investigators.","year":"2021","unstructured":"ATTACC Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 385, 790\u2013802 (2021).","journal-title":"N. Engl. J. Med."},{"key":"672_CR237","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","volume":"399","author":"E Ramacciotti","year":"2022","unstructured":"Ramacciotti, E. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 399, 50\u201359 (2022).","journal-title":"Lancet"},{"key":"672_CR238","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.2021.17272","volume":"326","author":"JM Connors","year":"2021","unstructured":"Connors, J. M. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA 326, 1703\u20131712 (2021).","journal-title":"JAMA"},{"key":"672_CR239","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(22)00175-2","volume":"9","author":"S Barco","year":"2022","unstructured":"Barco, S. et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol. 9, e585\u2013e593 (2022).","journal-title":"Lancet Haematol."},{"key":"672_CR240","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1093\/cid\/ciab813","volume":"75","author":"J Ananworanich","year":"2022","unstructured":"Ananworanich, J. et al. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin. Infect. Dis. 75, e473\u2013e481 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR241","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"INSPIRATION Investigators.","year":"2021","unstructured":"INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 325, 1620\u20131630 (2021).","journal-title":"JAMA"},{"key":"672_CR242","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.chest.2022.02.006","volume":"162","author":"LK Moores","year":"2022","unstructured":"Moores, L. K. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest 162, 213\u2013225 (2022).","journal-title":"Chest"},{"key":"672_CR243","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","volume":"5","author":"A Cuker","year":"2021","unstructured":"Cuker, A. et al. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 5, 872\u2013888 (2021).","journal-title":"Blood Adv."},{"key":"672_CR244","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/postgradmedj-2021-139923","volume":"98","author":"A Chandra","year":"2022","unstructured":"Chandra, A., Chakraborty, U., Ghosh, S. & Dasgupta, S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad. Med. J. 98, 395\u2013402 (2022).","journal-title":"Postgrad. Med. J."},{"key":"672_CR245","doi-asserted-by":"publisher","first-page":"101373","DOI":"10.1016\/j.eclinm.2022.101373","volume":"46","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: a systematic review and meta-analysis. eClinicalMedicine 46, 101373 (2022).","journal-title":"eClinicalMedicine"},{"key":"672_CR246","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1093\/cid\/ciac014","volume":"75","author":"A Marrone","year":"2022","unstructured":"Marrone, A. et al. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study. Clin. Infect. Dis. 75, e403\u2013e409 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR247","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160766","volume":"132","author":"G Shi","year":"2022","unstructured":"Shi, G. et al. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J. Clin. Invest. 132, e160766 (2022).","journal-title":"J. Clin. Invest."},{"key":"672_CR248","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/cid\/ciac769","volume":"76","author":"JI Hogan","year":"2023","unstructured":"Hogan, J. I. et al. Remdesivir resistance in transplant recipients with persistent COVID-19. Clin. Infect. Dis. 76, 342\u2013345 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"672_CR249","doi-asserted-by":"publisher","first-page":"100735","DOI":"10.1016\/j.xcrm.2022.100735","volume":"3","author":"A Heyer","year":"2022","unstructured":"Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. 3, 100735 (2022).","journal-title":"Cell Rep. Med."},{"key":"672_CR250","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","volume":"142","author":"G Li","year":"2017","unstructured":"Li, G. & De Clercq, E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir. Res. 142, 83\u2013122 (2017).","journal-title":"Antivir. Res."},{"key":"672_CR251","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges \u2032and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR252","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/nar\/gkac1177","volume":"51","author":"R Chinthapatla","year":"2023","unstructured":"Chinthapatla, R. et al. Interfering with nucleotide excision by the coronavirus 3\u2032-to-5\u2032 exoribonuclease. Nucleic Acids Res. 51, 315\u2013336 (2023).","journal-title":"Nucleic Acids Res."},{"key":"672_CR253","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.3390\/molecules27134292","volume":"27","author":"M Gohl","year":"2022","unstructured":"Gohl, M. et al. From repurposing to redesign: optimization of boceprevir to highly potent inhibitors of the SARS-CoV-2 main protease. Molecules 27, 4292 (2022).","journal-title":"Molecules"},{"key":"672_CR254","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1126\/science.abi4708","volume":"373","author":"TA Tummino","year":"2021","unstructured":"Tummino, T. A. et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science 373, 541\u2013547 (2021).","journal-title":"Science"},{"key":"672_CR255","doi-asserted-by":"publisher","first-page":"eabd5524","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley, C. G. et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 13, eabd5524 (2021).","journal-title":"Sci. Transl. Med."},{"key":"672_CR256","doi-asserted-by":"publisher","first-page":"eabg5995","DOI":"10.1126\/sciadv.abg5995","volume":"7","author":"MM Zaki","year":"2021","unstructured":"Zaki, M. M. et al. Cell therapy strategies for COVID-19: current approaches and potential applications. Sci. Adv. 7, eabg5995 (2021).","journal-title":"Sci. Adv."},{"key":"672_CR257","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541 (2019).","journal-title":"Antivir. Res."},{"key":"672_CR258","doi-asserted-by":"publisher","first-page":"105209","DOI":"10.1016\/j.antiviral.2021.105209","volume":"196","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors. Antivir. Res. 196, 105209 (2021).","journal-title":"Antivir. Res."},{"key":"672_CR259","doi-asserted-by":"publisher","first-page":"104924","DOI":"10.1016\/j.antiviral.2020.104924","volume":"182","author":"ZA Gurard-Levin","year":"2020","unstructured":"Gurard-Levin, Z. A. et al. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antivir. Res. 182, 104924 (2020).","journal-title":"Antivir. Res."},{"key":"672_CR260","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/molecules26040923","volume":"26","author":"G Li","year":"2021","unstructured":"Li, G. et al. Drug discovery of nucleos(t)ide antiviral agents: dedicated to Prof. Dr. Erik De Clercq on occasion of his 80th birthday. Molecules 26, 923 (2021).","journal-title":"Molecules"},{"key":"672_CR261","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","volume":"16","author":"KR Bewley","year":"2021","unstructured":"Bewley, K. R. et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat. Protoc. 16, 3114\u20133140 (2021).","journal-title":"Nat. Protoc."},{"key":"672_CR262","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3390\/v14071507","volume":"14","author":"E Bestion","year":"2022","unstructured":"Bestion, E., Halfon, P., Mezouar, S. & Mege, J. L. Cell and animal models for SARS-CoV-2 research. Viruses 14, 1507 (2022).","journal-title":"Viruses"},{"key":"672_CR263","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105912","volume":"40","author":"MM Lamers","year":"2021","unstructured":"Lamers, M. M. et al. An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. EMBO J. 40, e105912 (2021).","journal-title":"EMBO J."},{"key":"672_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00740-z","volume":"19","author":"Z Bukowy-Bieryllo","year":"2021","unstructured":"Bukowy-Bieryllo, Z. Long-term differentiating primary human airway epithelial cell cultures: how far are we. Cell Commun. Signal. 19, 63 (2021).","journal-title":"Cell Commun. Signal."},{"key":"672_CR265","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00097-21","volume":"65","author":"S Ramirez","year":"2021","unstructured":"Ramirez, S. et al. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antimicrob. Agents Chemother. 65, e0009721 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"672_CR266","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."},{"key":"672_CR267","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588\u2013590 (2020).","journal-title":"Nature"},{"key":"672_CR268","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2214-109X(20)30542-8","volume":"9","author":"JJH Park","year":"2021","unstructured":"Park, J. J. H. et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob. Health 9, e711\u2013e720 (2021).","journal-title":"Lancet Glob. Health"},{"key":"672_CR269","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/infdis\/jiac411","volume":"227","author":"FP Esper","year":"2023","unstructured":"Esper, F. P. et al. Alpha to omicron: disease severity and clinical outcomes of major SARS-CoV-2 variants. J. Infect. Dis. 227, 344\u2013352 (2023).","journal-title":"J. Infect. Dis."},{"key":"672_CR270","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jama.2021.22507","volume":"327","author":"JJH Park","year":"2022","unstructured":"Park, J. J. H., Detry, M. A., Murthy, S., Guyatt, G. & Mills, E. J. How to use and interpret the results of a platform trial: users\u2019 guide to the medical literature. JAMA 327, 67\u201374 (2022).","journal-title":"JAMA"},{"key":"672_CR271","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41591-020-1077-z","volume":"26","author":"KAO Tikkinen","year":"2020","unstructured":"Tikkinen, K. A. O., Malekzadeh, R., Schlegel, M., Rutanen, J. & Glasziou, P. COVID-19 clinical trials: learning from exceptions in the research chaos. Nat. Med. 26, 1671\u20131672 (2020).","journal-title":"Nat. Med."},{"key":"672_CR272","doi-asserted-by":"publisher","first-page":"n1648","DOI":"10.1136\/bmj.n1648","volume":"374","author":"H Crook","year":"2021","unstructured":"Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long covid-mechanisms, risk factors, and management. BMJ 374, n1648 (2021).","journal-title":"BMJ"},{"key":"672_CR273","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28, 1706\u20131714 (2022).","journal-title":"Nat. Med."},{"key":"672_CR274","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","volume":"328","author":"Global Burden of Disease Long COVID Collaborators","year":"2022","unstructured":"Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328, 1604\u20131615 (2022).","journal-title":"JAMA"},{"key":"672_CR275","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069676","volume":"377","author":"D Ayoubkhani","year":"2022","unstructured":"Ayoubkhani, D. et al. Trajectory of long covid symptoms after Covid-19 vaccination: community based cohort study. BMJ 377, e069676 (2022).","journal-title":"BMJ"},{"key":"672_CR276","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/d41586-022-02140-w","volume":"608","author":"H Ledford","year":"2022","unstructured":"Ledford, H. Long-COVID treatments: why the world is still waiting. Nature 608, 258\u2013260 (2022).","journal-title":"Nature"},{"key":"672_CR277","first-page":"793","volume":"609","author":"GJ Park","year":"2022","unstructured":"Park, G. J. et al. The mechanism of RNA capping by SARS-CoV-2. Nature 609, 793\u2013800 (2022).","journal-title":"Nature"},{"key":"672_CR278","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072117","volume":"378","author":"T Greenhalgh","year":"2022","unstructured":"Greenhalgh, T., Sivan, M., Delaney, B., Evans, R. & Milne, R. Long covid \u2014 an update for primary care. BMJ 378, e072117 (2022).","journal-title":"BMJ"},{"key":"672_CR279","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"672_CR280","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"672_CR281","doi-asserted-by":"publisher","first-page":"eabd0205","DOI":"10.1126\/sciimmunol.abd0205","volume":"6","author":"MJ Christie","year":"2021","unstructured":"Christie, M. J. et al. Of bats and men: immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci. Immunol. 6, eabd0205 (2021).","journal-title":"Sci. Immunol."},{"key":"672_CR282","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","volume":"30","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678\u2013692 (2020).","journal-title":"Cell Res."},{"key":"672_CR283","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1016\/j.cell.2022.09.037","volume":"185","author":"L Yan","year":"2022","unstructured":"Yan, L. et al. A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors. Cell 185, 4347\u20134360.e4317 (2022).","journal-title":"Cell"},{"key":"672_CR284","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1093\/nar\/gkab320","volume":"49","author":"S Lin","year":"2021","unstructured":"Lin, S. et al. Crystal structure of SARS-CoV-2 nsp10 bound to Nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Nucleic Acids Res. 49, 5382\u20135392 (2021).","journal-title":"Nucleic Acids Res."},{"key":"672_CR285","doi-asserted-by":"publisher","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","volume":"14","author":"A Schafer","year":"2022","unstructured":"Schafer, A. et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci. Transl. Med. 14, eabm3410 (2022).","journal-title":"Sci. Transl. Med."},{"key":"672_CR286","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/jac\/dkaa239","volume":"75","author":"M Tempestilli","year":"2020","unstructured":"Tempestilli, M. et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J. Antimicrob. Chemother. 75, 2977\u20132980 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"672_CR287","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","volume":"2","author":"M Cevik","year":"2021","unstructured":"Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2, e13\u2013e22 (2021).","journal-title":"Lancet Microbe"},{"key":"672_CR288","doi-asserted-by":"publisher","first-page":"811","DOI":"10.7326\/M20-7547","volume":"174","author":"I Arkhipova-Jenkins","year":"2021","unstructured":"Arkhipova-Jenkins, I. et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann. Intern. Med. 174, 811\u2013821 (2021).","journal-title":"Ann. Intern. Med."},{"key":"672_CR289","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(22)01214-4","volume":"400","author":"AV Ballering","year":"2022","unstructured":"Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C. & Rosmalen, J. G. M., Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 400, 452\u2013461 (2022).","journal-title":"Lancet"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00672-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T18:56:23Z","timestamp":1702234583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":289,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00672-y","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"28 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H. filed a patent application covering \u03b1-ketoamide M<sup>pro<\/sup> inhibitors of the 13b family. He discloses a research collaboration with Atea Pharmaceuticals. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}